JP2005538930A - ヒトｆｏｘｃ２タンパク質およびｆｏｘｃ−２相互作用タンパク質の複合体 - Google Patents
ヒトｆｏｘｃ２タンパク質およびｆｏｘｃ−２相互作用タンパク質の複合体 Download PDFInfo
- Publication number
- JP2005538930A JP2005538930A JP2003564087A JP2003564087A JP2005538930A JP 2005538930 A JP2005538930 A JP 2005538930A JP 2003564087 A JP2003564087 A JP 2003564087A JP 2003564087 A JP2003564087 A JP 2003564087A JP 2005538930 A JP2005538930 A JP 2005538930A
- Authority
- JP
- Japan
- Prior art keywords
- foxc2
- polypeptide
- seq
- protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 114
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 105
- 108700017904 mesenchyme fork head 1 Proteins 0.000 title claims abstract description 21
- 102100021083 Forkhead box protein C2 Human genes 0.000 claims abstract description 102
- 101000818305 Homo sapiens Forkhead box protein C2 Proteins 0.000 claims abstract description 102
- 230000000694 effects Effects 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 48
- 239000000126 substance Substances 0.000 claims abstract description 45
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 16
- 208000008589 Obesity Diseases 0.000 claims abstract description 10
- 235000020824 obesity Nutrition 0.000 claims abstract description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 8
- 235000005911 diet Nutrition 0.000 claims abstract description 7
- 230000037213 diet Effects 0.000 claims abstract description 7
- 208000006575 hypertriglyceridemia Diseases 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 90
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 89
- 229920001184 polypeptide Polymers 0.000 claims description 88
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 37
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 208000022531 anorexia Diseases 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 102100027703 Heterogeneous nuclear ribonucleoprotein H2 Human genes 0.000 abstract description 11
- 101001081143 Homo sapiens Heterogeneous nuclear ribonucleoprotein H2 Proteins 0.000 abstract description 10
- 101000583854 Homo sapiens Activating transcription factor 7-interacting protein 1 Proteins 0.000 abstract description 9
- 102100030963 Activating transcription factor 7-interacting protein 1 Human genes 0.000 abstract description 8
- 101100496169 Arabidopsis thaliana CLH1 gene Proteins 0.000 abstract description 7
- 102000007474 Multiprotein Complexes Human genes 0.000 abstract description 4
- 108010085220 Multiprotein Complexes Proteins 0.000 abstract description 4
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 3
- 102000020233 phosphotransferase Human genes 0.000 abstract description 3
- 102100027421 Heat shock cognate 71 kDa protein Human genes 0.000 abstract 1
- 101001080568 Homo sapiens Heat shock cognate 71 kDa protein Proteins 0.000 abstract 1
- 101001038562 Homo sapiens Nucleolar protein 4 Proteins 0.000 abstract 1
- 102100040316 Nucleolar protein 4 Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 14
- 230000003993 interaction Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 229930182830 galactose Natural products 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 102000016914 ras Proteins Human genes 0.000 description 5
- 108010014186 ras Proteins Proteins 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010011122 A Kinase Anchor Proteins Proteins 0.000 description 4
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 4
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000004850 protein–protein interaction Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- 102000005853 Clathrin Human genes 0.000 description 3
- 108010019874 Clathrin Proteins 0.000 description 3
- 101100013373 Homo sapiens FOXC2 gene Proteins 0.000 description 3
- 102000002813 MafB Transcription Factor Human genes 0.000 description 3
- 108010004890 MafB Transcription Factor Proteins 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 102000007999 Nuclear Proteins Human genes 0.000 description 3
- 108010089610 Nuclear Proteins Proteins 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 101150069072 cdc25 gene Proteins 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229930193282 clathrin Natural products 0.000 description 3
- 238000000749 co-immunoprecipitation Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 2
- 101100457919 Drosophila melanogaster stg gene Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101150031823 HSP70 gene Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 108060001643 clathrin heavy chain Proteins 0.000 description 2
- 102000014907 clathrin heavy chain Human genes 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 101150052825 dnaK gene Proteins 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000037426 transcriptional repression Effects 0.000 description 2
- 238000001086 yeast two-hybrid system Methods 0.000 description 2
- 102100031912 A-kinase anchor protein 1, mitochondrial Human genes 0.000 description 1
- 101710160275 A-kinase anchor protein 1, mitochondrial Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101150026630 FOXG1 gene Proteins 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- 102100020871 Forkhead box protein G1 Human genes 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 1
- 108020004996 Heterogeneous Nuclear RNA Proteins 0.000 description 1
- 102100027738 Heterogeneous nuclear ribonucleoprotein H Human genes 0.000 description 1
- 101710203726 Heterogeneous nuclear ribonucleoprotein H2 Proteins 0.000 description 1
- 108010052492 Heterogeneous-Nuclear Ribonucleoprotein Group F-H Proteins 0.000 description 1
- 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 description 1
- 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241001327682 Oncorhynchus mykiss irideus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101150117474 Sos gene Proteins 0.000 description 1
- 108010053551 Sp1 Transcription Factor Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102100030246 Transcription factor Sp1 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200265A SE0200265D0 (sv) | 2002-01-29 | 2002-01-29 | Protein complexes |
| US37734902P | 2002-04-30 | 2002-04-30 | |
| PCT/SE2003/000139 WO2003064467A1 (en) | 2002-01-29 | 2003-01-28 | A complex of a human foxc2 protein and a foxc2-interacting protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005538930A true JP2005538930A (ja) | 2005-12-22 |
| JP2005538930A5 JP2005538930A5 (enExample) | 2006-03-16 |
Family
ID=27667646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003564087A Pending JP2005538930A (ja) | 2002-01-29 | 2003-01-28 | ヒトｆｏｘｃ２タンパク質およびｆｏｘｃ−２相互作用タンパク質の複合体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7217692B2 (enExample) |
| EP (1) | EP1468017A1 (enExample) |
| JP (1) | JP2005538930A (enExample) |
| WO (1) | WO2003064467A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008540586A (ja) * | 2005-05-18 | 2008-11-20 | フォルシュングスフェアブント ベルリン エー ファウ | Ａｋａｐ−ｐｋａ相互作用の非ペプチド阻害剤 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
| WO2008086090A1 (en) * | 2007-01-05 | 2008-07-17 | University Of Washington | Self-assembled heterogeneous integrated optical analysis system |
| US8579434B2 (en) | 2007-11-07 | 2013-11-12 | University Of Washington Through Its Center For Commercialization | Free-standing two-sided device fabrication |
| US11235062B2 (en) * | 2009-03-06 | 2022-02-01 | Metaqor Llc | Dynamic bio-nanoparticle elements |
| US11096901B2 (en) * | 2009-03-06 | 2021-08-24 | Metaqor Llc | Dynamic bio-nanoparticle platforms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9701963D0 (sv) * | 1997-05-26 | 1997-05-26 | Pharmacia & Upjohn Ab | Novel transcription factor |
| AU2001232599B2 (en) * | 2000-02-18 | 2006-10-12 | Leangene Ab | Transgenic animal model for obesity expressing foxc2 |
| AU2001292481A1 (en) * | 2000-09-26 | 2002-04-08 | Leangene Ab | Promoter sequences |
-
2003
- 2003-01-28 WO PCT/SE2003/000139 patent/WO2003064467A1/en not_active Ceased
- 2003-01-28 EP EP03734938A patent/EP1468017A1/en not_active Withdrawn
- 2003-01-28 JP JP2003564087A patent/JP2005538930A/ja active Pending
- 2003-01-28 US US10/500,941 patent/US7217692B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008540586A (ja) * | 2005-05-18 | 2008-11-20 | フォルシュングスフェアブント ベルリン エー ファウ | Ａｋａｐ−ｐｋａ相互作用の非ペプチド阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060052293A1 (en) | 2006-03-09 |
| EP1468017A1 (en) | 2004-10-20 |
| WO2003064467A1 (en) | 2003-08-07 |
| US7217692B2 (en) | 2007-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001009317A1 (fr) | Gene associe au cancer de l'estomac | |
| JP2000078991A (ja) | ヒト・ナトリウム依存性リン酸輸送体（ｉｐｔ―１） | |
| JP2002521055A (ja) | ９８個のヒト分泌タンパク質 | |
| CN1093406A (zh) | 可分离的编码肿瘤排斥抗原前体的核酸序列 | |
| US20250283871A1 (en) | Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes | |
| JP2001508656A (ja) | ヒトｍａｇｅ様タンパク質 | |
| JP2001527524A (ja) | ヒト乳房腫瘍特異性タンパク質 | |
| US6323329B1 (en) | Nucleic acid sequences of genes encoding high mobility group proteins | |
| JP2003524366A (ja) | ６４個のヒト分泌タンパク質 | |
| JP2005538930A (ja) | ヒトｆｏｘｃ２タンパク質およびｆｏｘｃ−２相互作用タンパク質の複合体 | |
| US6043084A (en) | Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer | |
| JP2001506850A (ja) | 脂肪細胞特異的分化関連タンパク質 | |
| US20020086384A1 (en) | Splice variants of oncogenes | |
| JP2003521215A (ja) | ８３個のヒト分泌タンパク質 | |
| JP2001511645A (ja) | ヒトＣ５ａ様受容体 | |
| US7087717B2 (en) | Sp110, a polypeptide component of the nuclear body | |
| JPH1156376A (ja) | ヒトＩκＢ−β | |
| JP2001501802A (ja) | ハンチンチン（ｈｕｎｔｉｎｇｔｉｎ）結合蛋白質 | |
| US20020142003A1 (en) | Tumor-associated antigen (B345) | |
| JPH11151094A (ja) | 免疫グロブリン遺伝子スーパーファミリーのメンバーｐｉｇｒｌ−１ | |
| EP1428891A1 (en) | Novel gene nedl-1 | |
| JP2002527028A (ja) | ヒトアポトーシス調節タンパク質 | |
| JP2001527522A (ja) | ヒトｇタンパク質シグナル伝達制御因子（ｈｒｇｓ） | |
| JP2001509015A (ja) | ヒト塩素イオンチャネルタンパク質（ｈｃｃｐ） | |
| JP2001512968A (ja) | ヒトｐ２４小胞タンパク質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081104 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090331 |